Furthermore, TCZ was shown to be efficacious in patients with reactive HLH or macrophage activation syndrome (MAS) in a few case reports, suggesting that IL-6 blockade could be a potential therapeutic target in sHLH [11, 19]. The gene discussed is IL6; the disease is hemophagocytic syndrome.